treatment after the tension had been measured on arrival. If no rise in tension occurred, guanethidine 5 per cent. was added to the original treatment for use by the patient himself.
The patient was then phased on full treatment at a later date. Other treatments were subsequently reduced in strength or frequency or eliminated at later visits.
Some patients were already receiving either adrenaline or guanethidine before the trial. In these cases the protocol was altered appropriately. Thus at the end of the trial all patients were receiving guanethidine drops 5 per cent. twice daily and neutral adrenaline drops o 25 per cent. as a minimum treatment.
The number of patients in the trial was 29, and the number of eyes involved was 49. Where only one eye from one patient was included in the trial the other presented no clinical problem.
The diagnostic classification of the eyes included are shown in the 
Results
The 9.30 a.m. tension at the first visit (i.e. on the treatment used at the time of referral) was compared with the 9.30 a.m. tension at the next visit when both guanethidine and adrenaline drops had been added to the treatment. Two patients (4 eyes) were unable to continue the treatment because of side-effects. One of them developed ptosis and conjunctival hyperaemia which recovered when guanethidine was stopped, and one developed headache and gross reactive hyperaemia which ceased when adrenaline was withdrawn.
Seven patients (9 eyes) can be regarded as failures because it was decided after the trial that operation was necessary, medical treatment having failed to provide consistent satisfactorily low IOPs.
Follow-up
Patients involved in the trial were followed up in the Glaucoma Clinic for a minimum 6 months. The mean follow-up period was I I months.
Of the 36 eyes in 20 patients, which remained in the trial, two patients (2 eyes) proved unable to cope with self-administration of drops and one patient (2 eyes) no longer required treatment because a few months after an unintentional lapse in medication no further high tensions were recorded.
Of the remaining 32 eyes (I 7 patients), seven were taken off guanethidine and adrenaline after a few weeks because tensions recorded at midday were high.
Thus, over a mean period of i i months, the total number of failures due to any cause was 24 eyes, and the final number of eyes still on treatment was 25.
Discussion
These patients were selected for the trial because their tensions were poorly controlled or because they were losing visual field in spite of apparently satisfactory tensions. They do not represent a typical group of patients with glaucoma.
It is difficult to decide what constitutes control of IOP, but comparing IOP levels at a certain tinme of day is one way in which the results of the trial can be subjected to statistical analysis; on this basis a significance level of 5 per cent. is an indication at least that the drug combination was effective. The criteria of improvement in this experiment relate only to 9.30 a.m. IOPs and not to other factors such as control of field loss. It is evident that 9.30 a.m. tensions do not give an indication of the degree of control over a 24-hour period. In some of these patients it was midday tension that was high while the early readings were satisfactory. Altogether thirteen of 49 eyes were definitely not benefited by guanethidine and adrenaline, four because of side-effects and nine because the intraocular pressure was not considered to be adequately controlled by the surgeons in charge of the patients. This represents an initial failure rate of 26-5 per cent. and an improvement rate of 73'5 per cent.
Over the follow-up period a further I I eyes were withdrawn from the trial for the reasons stated earlier. Thus the total number of failures was 24 eyes which represents a success rate of 50 per cent.
Ptosis is not a frequent side-effect of guanethidine. Castren and Pohjola (I962) and Trzcin'ska-Dabrowska and Majewska (I 970) found no ptosis. Kutschera (i 96 I), however, reported its occurrence. Merte and Toppel (i960) reported conjunctival irritation as a side-effect but did not notice any ptosis. Brow ache was mentioned as a side-effect of adrenaline by Drance (i 962) .
If it is considered that, as a result of adding guanethidine and adrenaline to the treatment (or substituting it for other treatment), 50 per cent. of these eyes did not require operation, then the result of the trial was satisfactory. It should be remembered that all eyes involved in the trial had already proved difficult to control and would probably have required surgery had they not received guanethidine and adrenaline.
Although no detailed clinical studies have been done on this subject it may be possible to use weaker solutions of adrenaline than o 25 per cent. in combination with guanethidine to obtain an adequate level of control of IOP.
Summary
Guanethidine 5 per cent. and adrenaline o25 per cent. or o05 per cent. drops were used together in an attempt to provide adequate control of intraocular pressure in eyes which had proved difficult to manage on other medical treatment.
The results of the trial suggest that the combination was effective by virtue of the synergistic actions of guanethidine and adrenaline. 
